Brain-Computer Interface Company Synchron Raises $200 Million
Synchron, a New York-based company specializing in non-surgical brain-computer interface (BCI) technology, has secured $200 million in a series D funding round. This investment will speed up the commercialization of its first-generation Stentrode BCI platform and support the development of an advanced next-generation interface.
Funding and Investors
The latest financing round increases Synchron's total funding to $345 million. Double Point Ventures led the investment, joined by existing backers ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New investors include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
The Stentrode BCI Platform
Synchron’s Stentrode is the first endovascular brain-computer interface, designed to decode brain activity into digital commands without requiring open-brain surgery. The device is implanted via a minimally invasive catheter procedure, connecting to the motor cortex through blood vessels. It records and wirelessly transmits neural signals, enabling hands-free control of digital devices.
The Stentrode BCI platform is "designed to translate brain activity into digital commands without open-brain surgery."
Author's summary: Synchron's $200 million funding round aims to accelerate the launch of its groundbreaking Stentrode brain-computer interface and drive development of its next-generation technology.